## CITATION REPORT List of articles citing

FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system

DOI: 10.1016/j.medj.2021.06.007 Med, 2021, 2, 979-992.e8.

Source: https://exaly.com/paper-pdf/81637418/citation-report.pdf

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
96	Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. <i>Morbidity and</i>	31.7	363
95	Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study.		9
94	Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers. <i>Infection Control and Hospital Epidemiology</i> , <b>2021</b> , 1-2	2	5
93	Gene therapy avenues and COVID-19 vaccines. <i>Genes and Immunity</i> , <b>2021</b> , 22, 120-124	4.4	6
92	The SARS-CoV-2 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus shedding, and viral genetic diversity. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	12
91	Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. <i>Eurosurveillance</i> , <b>2021</b> , 26,	19.8	31
90	Role of the Renin-Angiotensin-Aldosterone and Kinin-Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	10
89	Projecting the Impact of SARS-CoV-2 Variants and the Vaccination Program on the Fourth Wave of the COVID-19 Pandemic in South Korea. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	12
88	SARS-CoV-2 vaccination in patients with inflammatory bowel disease. <i>GastroHep</i> , <b>2021</b> , 3, 212-228	1	1
87	Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory.		13
86	Effectiveness of COVID-19 vaccines: findings from real world studies. <i>Medical Journal of Australia</i> , <b>2021</b> , 215, 149-151.e1	4	12
85	Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2. <i>PLoS ONE</i> , <b>2021</b> , 16, e0254734	3.7	1
84	COVID-19 vaccination passport: prospects, scientific feasibility, and ethical concerns. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 1-4	4.4	12
83	Transmissibility of COVID-19 among Vaccinated Individuals: A Rapid Literature Review - Update #1.		3
82	Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. <i>Med</i> , <b>2021</b> , 2, 965-978.e5	31.7	13
81	Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. <b>2021</b> ,		82
80	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , <b>2021</b> , 54, 1636-1651	32.3	32

Low risk of SARS-CoV-2 transmission via fomite, even in cold-chain. 2021, 2 79 Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ, The, 78 5.9 79 **2021**, 374, n1943 Population Immunity Against COVID-19 in the United States. Annals of Internal Medicine, 2021, 174, 158&15914 77 Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T 76 60 33.3 cells. Science, **2021**, 374, eabj9853 Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA 75 4.1 4 vaccine by commercial antibody tests. Vaccine, 2021, 39, 5563-5570 Prevention of host-to-host transmission by SARS-CoV-2 vaccines. Lancet Infectious Diseases, The, 74 25.5 15 2021, Population science with individual-level data make for better policies. Lancet Respiratory Ο 73 35.1 Medicine, the, 2021, 9, 942-943 A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection 72 10 and disease. Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. 71 3 A look into the future of the COVID-19 pandemic in Europe: an expert consultation. Lancet Regional 70 30 Health - Europe, The, 2021, 8, 100185 MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. 69 4 4 Multiple Sclerosis and Related Disorders, 2021, 56, 103225 The challenges to a successful COVID-19 vaccination programme in Africa. Germs, 2021, 11, 427-440 68 Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against 67 9.5 77 SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection, 2021, Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: 66 16 test-negative design studies from British Columbia and Quebec, Canada. COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. Vaccines, 2021, 9, 65 6 5.3 Symptom monitoring after coronavirus disease 2019 (COVID-19) vaccination in a large integrated 64 healthcare system: Separating symptoms from severe acute respiratory coronavirus virus 2 2 (SARS-CoV-2) infection. Infection Control and Hospital Epidemiology, 2021, 1-8 Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing 63 10.4 21 COVID-19. JAMA Network Open, 2021, 4, e2132540 Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and 62 10.4 51 meta-analysis. Infectious Diseases of Poverty, 2021, 10, 132

61	Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here. <i>BMC Public Health</i> , <b>2021</b> , 21, 2084	4.1	2
60	Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. <i>International Journal of Infectious Diseases</i> , <b>2021</b> ,	10.5	60
59	Higher Vaccination Rate Predicts Reduction in SARS-CoV-2 Transmission across the United States. <b>2021</b> ,		
58	Three doses of COVID-19 mRNA vaccination are safe based on adverse events reported in electronic health records.		О
57	Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary - The HUN-VE study. <i>Clinical Microbiology and Infection</i> , <b>2021</b> ,	9.5	22
56	Reactogenicity of COVID-19 vaccine in hemodialysis patients: a single-center retrospective study.		
55	The impact of vaccination on the evolution of COVID-19 in Portugal <i>Mathematical Biosciences and Engineering</i> , <b>2022</b> , 19, 936-952	2.1	4
54	Evaluation of protection by COVID-19 vaccines after deployment in low and lower-middle income countries <i>EClinicalMedicine</i> , <b>2022</b> , 43, 101253	11.3	1
53	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection <i>Med</i> , <b>2021</b> ,	31.7	2
52	Tafenoquine and its derivatives as inhibitors for the Severe Acute Respiratory Syndrome Coronavirus 2 <i>Journal of Biological Chemistry</i> , <b>2022</b> , 101658	5.4	1
51	Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality <i>Clinical Reviews in Allergy and Immunology</i> , <b>2022</b> , 1	12.3	10
50	Effectiveness of Vaccination against SARS-CoV-2 Infection in the Pre-Delta Era: A Systematic Review and Meta-Analysis <i>Vaccines</i> , <b>2022</b> , 10,	5.3	4
49	Brief report of real-world evidence development (RWD/RWE) in 2021: United States, Russia, and the Eurasian Economic Union (EAEU). <b>2022</b> , 2, 1-9		3
48	SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study <i>Vaccine</i> , <b>2021</b> , 40, 206-206	4.1	4
47	Decontamination of SARS-CoV-2 from cold-chain food packaging provides no marginal benefit in risk reduction to food workers <i>Food Control</i> , <b>2022</b> , 136, 108845	6.2	2
46	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review <i>Human Vaccines and Immunotherapeutics</i> , <b>2022</b> , 1-2	0 <sup>4.4</sup>	14
45	Analysis of COVID-19 Risk Following a Ring Vaccination Intervention to Address SARS-CoV-2 Alpha Variant Transmission in Montreal, Canada <i>JAMA Network Open</i> , <b>2022</b> , 5, e2147042	10.4	0
44	Can a combination of vaccination and face mask wearing contain the COVID-19 pandemic?. <i>Microbial Biotechnology</i> , <b>2021</b> ,	6.3	8

43	Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study <i>Vaccines</i> , <b>2021</b> , 9,	5.3	24
42	Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 438	21	9
41	Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP) <i>Viruses</i> , <b>2022</b> , 14,	6.2	2
40	Waning COVID-19 vaccine effectiveness in Japan <i>Drug Discoveries and Therapeutics</i> , <b>2022</b> , 16, 30-36	5	О
39	Long COVID-19 and Postural Orthostatic Tachycardia Syndrome- Is Dysautonomia to Be Blamed?. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 860198	5.4	2
38	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac124	1	3
37	COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January-30 June 2021) <i>Vaccines</i> , <b>2022</b> , 10,	5.3	3
36	Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 839922	8.4	5
35	Rapid method through routine data to evaluate real-world vaccine effectiveness against coronavirus disease 2019 (COVID-19) infection: lessons from Thailand <i>Health Research Policy and Systems</i> , <b>2022</b> , 20, 29	3.7	1
34	Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine <i>Cancer Journal (Sudbury, Mass )</i> , <b>2022</b> , 28, 146-150	2.2	
33	Higher vaccination rates predict reduction in SARS-CoV-2 transmission across the United States <i>Infection</i> , <b>2022</b> , 1	5.8	1
32	Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study <i>American Journal of Epidemiology</i> , <b>2022</b> ,	3.8	6
31	Competitive fitness of emerging SARS-CoV-2 variants is linked to their Distinctiveness relative to preceding lineages from that region.		
30	Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021 <i>Vaccines</i> , <b>2021</b> , 9,	5.3	6
29	Persistence of immune response in health care workers after two doses BNT162b2 in a longitudinal observational study.		
28	Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination <i>Vaccine</i> , <b>2022</b> ,	4.1	3
27	Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records JAMA Network Open, <b>2022</b> , 5, e227038	10.4	1
26	A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease. <i>Open Forum Infectious Diseases</i> ,	1	3

25	COVID-19 vaccination challenges: a mini-review <i>Human Vaccines and Immunotherapeutics</i> , <b>2022</b> , 1-9	4.4	0
24	Population-Level Effectiveness of COVID-19 Vaccination Program in the United States: Causal Analysis Based on Structural Nested Mean Model. <i>Vaccines</i> , <b>2022</b> , 10, 726	5.3	O
23	Differential anchoring effects of vaccination comparator selection: characterizing a potential bias due to healthcare utilization in COVID-19 versus influenza <i>JMIR Public Health and Surveillance</i> , <b>2022</b> ,	11.4	О
22	A Retrospective Analysis of Risk Factors Associated with the SARS-CoV-2 Breakthrough in Fully mRNA Vaccinated Individuals <i>JMIR Public Health and Surveillance</i> , <b>2022</b> ,	11.4	1
21	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19.		O
20	Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. <i>Vaccines</i> , <b>2022</b> , 10, 938	5.3	2
19	Expert Review on global real-world vaccine effectiveness against SARS-CoV-2. Expert Review of Vaccines,	5.2	1
18	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure.		
17	The effect of COVID-19 mRNA vaccines against postvaccination laboratory-confirmed SARS-CoV-2 infection, symptomatic COVID-19 infection, hospitalization, and mortality rate: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> ,	5.2	0
16	Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo. <i>Advanced Science</i> , 2201294	13.6	O
15	Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine. 13,		О
14	Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021. <b>2022</b> , 5, e2220385		8
13	Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice. <b>2022</b> , 10, 1305		0
12	COVID-19 Infection and Response to Vaccination in Chronic Kidney Disease and Renal Transplantation: A Brief Presentation. <b>2022</b> , 12, 1358		1
11	The Silver Lining of the COVID-19 Pandemic: Fast-Tracked Vaccine Production and Approval.		0
10	A novel drug selection decision support model based on real-world medical data by the hybrid entropic weight TOPSIS method. <b>2022</b> , 1-13		O
9	Evolutionary Pattern Comparisons of the SARS-CoV-2 Delta Variant in Countries/Regions with High and Low Vaccine Coverage. <b>2022</b> , 14, 2296		1
8	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. 13,		1

## CITATION REPORT

7	The importance of sustained compliance with physical distancing during COVID-19 vaccination rollout. <b>2022</b> , 2,	O
6	Comparative analysis of the effectiveness of vaccines against SARS-CoV-2 3 months after revaccination. <b>2022</b> , 3, 32-35	O
5	Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study. <b>2023</b> , 104548	O
4	An integrated chance constraints approach for optimal vaccination strategies under uncertainty for COVID-19. <b>2023</b> , 101547	O
3	Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium. <b>2023</b> , 11, 378	О
2	Effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. <b>2023</b> , 95,	1
1	Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. <b>2023</b> , 19.	О